NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, will report its fiscal third quarter 2026 financial results before market open on Thursday, August 13, 2026. The company will host an investor conference call and webcast at 8:30 a.m. Eastern time the same day to discuss the results, provide a corporate update, and answer questions from participants.
The earnings call is a key event for investors and industry observers, as it will offer insights into the company's performance during the quarter ended June 30, 2026. NeuroOne has been at the forefront of developing minimally invasive, high-definition electrode technology, with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for the brain, and OneRF® Trigeminal Nerve Ablation System. These products are designed to potentially reduce hospitalizations and surgical procedures, lower healthcare costs, and improve patient outcomes by combining diagnostic and therapeutic functions.
The upcoming financial results and corporate update are particularly significant given the company's ongoing research and development efforts in drug delivery, basivertebral nerve ablation, and spinal cord stimulation. These programs could expand NeuroOne's market reach and address a broader range of neurological conditions. For leaders in business and technology, the call will provide a window into the company's strategic direction, operational progress, and financial health, which are critical for assessing its competitive position in the medical device industry.
Investors and stakeholders can participate in the call by dialing 888-506-0062 (U.S. toll-free) or 973-528-0011 (international), using participant access code 549778. The webcast will be available at NMTC FY Q3 2026 Earnings Call Webcast. Participants are advised to join at least five minutes before the start to ensure timely access.
A replay of the call will be available through August 27, 2026, by dialing 877-481-4010 (U.S.) or 919-882-2331 (international) with replay passcode 54304. Additionally, a webcast replay will be accessible through the same link until August 13, 2027, allowing those who missed the live event to catch up on the details.
NeuroOne's focus on transforming surgical diagnosis and treatment aligns with broader trends in precision medicine and minimally invasive procedures. The company's technology platform, which includes both diagnostic and therapeutic capabilities, could play a pivotal role in advancing neurological care. As the company continues to innovate and expand its product pipeline, the outcomes of this fiscal quarter and the management's commentary will be closely watched by industry analysts and healthcare technology enthusiasts.
The announcement of the financial results comes at a time when the medical technology sector is experiencing rapid advancements, and NeuroOne's developments could have significant implications for patients, healthcare providers, and the industry as a whole. By delivering high-precision electrode systems and ablation solutions, the company aims to address unmet needs in neurosurgery and pain management, potentially setting new standards of care.
For more information about NeuroOne and its products, visit the company's website at nmtc1.com. The company's commitment to research and development in areas like drug delivery and spinal cord stimulation underscores its ambition to remain at the cutting edge of neurological therapeutics.
